Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD(TM), PrecisionCHD(TM) and the HeartRisk(TM) population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes.
The news, reported via NewMediaWire, underscores the growing intersection of artificial intelligence and employee benefits management. Cardiovascular disease remains the leading cause of death globally and a major contributor to employer healthcare expenditures. By leveraging AI-driven genetic and epigenetic analysis, Cardio Diagnostics aims to shift the paradigm from reactive treatment to early detection and prevention, potentially reducing the burden on health plans and improving workforce productivity.
For benefits decision-makers, the implications are significant. Traditional risk assessments often rely on factors like age, cholesterol and blood pressure, which can miss individuals with underlying genetic predispositions. Cardio Diagnostics’ tests, such as Epi+Gen CHD and PrecisionCHD, integrate epigenetic markers and genetic data to provide a more precise risk profile. The HeartRisk platform offers population-level insights, enabling employers and plan administrators to identify high-risk groups and tailor wellness programs accordingly.
This move comes as employers seek innovative ways to contain healthcare costs, which have been rising steadily. According to the company, cardiovascular disease is a primary driver of both direct medical expenses and indirect costs from absenteeism and presenteeism. By identifying at-risk individuals earlier, Cardio Diagnostics’ solutions could help reduce the incidence of heart attacks and strokes, which often lead to expensive emergency care and long-term disability.
The company’s participation in four national benefits conferences in June signals a targeted effort to reach key stakeholders in the employee benefits ecosystem. These events typically attract benefits managers, brokers, union trustees and plan administrators who are actively searching for data-driven tools to optimize health plan performance. Cardio Diagnostics’ AI-powered offerings align with the broader trend of precision medicine and population health management, where data analytics and genomics are used to personalize prevention strategies.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease.
Forward-looking statements in the announcement caution that actual results may differ materially due to risks and uncertainties, including those detailed in the company’s SEC filings. The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.
